

CURRICULUM VITAE

Janet Robertson Casey**BUSINESS ADDRESS**

Legacy Pediatrics
 1815 S. Clinton Ave, Suite 360
 Rochester, New York 14618
 Phone: (585) 568-8330
 Fax: (585) 568-8327
 Email: jrcasey@legacypediatrics.com

HOME ADDRESS

3 Lily Pond Lane
 Pittsford, New York 14532

BIRTHDATE

April 18, 1961

BIRTHPLACE

Pasadena, California

MEDICAL LICENSE NUMBER

New York State: 202362

CITIZENSHIP

United States of America

EDUCATION**INSTITUTION AND LOCATION**

Stanford University, Stanford, California
 Human Biology
 Case Western Reserve University School
 of Medicine, Cleveland, Ohio

DEGREE

A.B.

M.D.

YEAR

1983

1987

PROFESSIONAL TRAINING AND EXPERIENCE

1987-90	Resident, University of Washington, Department of Pediatrics Seattle, Washington
1990-93	Fellow, Duke University Medical Center, Department of Pediatrics, Division of Pediatric Hematology-Oncology Durham, North Carolina
1993-95	Associate in Pediatrics, Duke University Medical Center, Department of Pediatrics, Division of Pediatric Hematology-Oncology Durham, North Carolina
1995-96	Assistant Professor in Pediatrics, Duke University Medical Center, Department of Pediatrics, Division of Pediatric Hematology-Oncology Durham, North Carolina
1996-2001	Clinical Instructor, University of Rochester, Department of Pediatrics, Rochester, New York
2001-2004	Clinical Assistant Professor of Pediatrics, University of Rochester, Department of Pediatrics Rochester, New York

2004-2017 Clinical Associate Professor of Pediatrics, University of Rochester,
Department of Pediatrics
Rochester, New York

2017- Clinical Professor of Pediatrics, University of Rochester,
Department of Pediatrics
Rochester, New York

CLINICAL PRACTICE ACTIVITIES

2007-present Partner, Legacy Pediatrics, Rochester, New York

1996-2007 Partner, The Elmwood Pediatric Group, Rochester, New York

HONORS AND AWARDS

Graduated with Distinction

Stanford University, 1983

Student Research Grant

Case Western Reserve University, 1984

Henry F. Saunders Award in Pediatrics

Case Western Reserve University, 1987

Alpha Omega Alpha

Case Western Reserve University, 1987

Burtis Burr Breese Award in Pediatric Infectious Diseases, 2005

Best Doctors in America, 2005-2017

Best Pediatricians in America, 2005-2017

INVITED LECTURESHIPS

2015 Franklin L. Debusk, MD Annual Lecture in Pediatrics University of Florida
Department of Pediatrics March 12, 2015.

The Microbiology and Immunology of Acute Otitis Media: *A Pediatric Practice's Contribution*

MEDICAL LICENSURE

Washington, 1987-1990

North Carolina, 1990-1996

New York, 1996-present

SPECIALTY BOARDS

American Board of Pediatrics, 1990, Recertification, 1997, 2004, 2011, 2016

American Board of Pediatric Hematology-Oncology, 1994, Recertification, 2000

RESEARCH

1991-1993 Duke University Medical Center, Department of Medicine, Division of
Hematology-Oncology, Advisor-Dr. Wendell Rosse, Project: Investigation
of the genomic structure of the urokinase plasminogen activator receptor
gene

1993-1996 Associate Member of Pediatric Oncology Group (POG) with participation
in clinical research protocols

- 1996-2007 Co-director of research at the Elmwood Pediatric Group
- 2007-present Director of research at Legacy Pediatrics
- 2000-2007 Principal investigator for the Elmwood Pediatric Group subcontract to the University of Rochester NIH Vaccine and Treatment Evaluation Contract (John Treanor, P.I.)
- 2007-2008 Principal investigator for Legacy Pediatrics subcontract to the University of Rochester NIH Vaccine and Treatment Evaluation Contract (John Treanor, P.I.)
1. An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Johnson & Johnson Pharmaceutical Research. 2002-2004.
 2. A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders that Occur After Initiating a Course of Levofloxacin (RWJ-25213-097) or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Clinical Trials Involving Levofloxacin Therapy Protocol LOFBO-LTSS-001 (PRI/LOF-INT-4) Phase 3. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Johnson & Johnson Pharmaceutical Research. 2002-2004.
 3. An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects with Acute Otitis Media. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Abbott Laboratories. 2002-2003.
 4. Observational Study to Monitor Compliance with the Routine Use of Cefdinir 5-day Therapy and Amoxicillin-Clavulanate ES 10-day Therapy in Young Children with Acute Otitis Media. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Abbott Laboratories. 2003.
 5. Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD: Protocol MTA17. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Aventis Pasteur Inc. 2003-2004.
 6. Pediatric Links with the Community. Impact of Tympanocentesis on the Rate of Persistent/Recurrent Acute Otitis Media Infections and the number of Referrals for PET Placement. 2003-2004.
 7. A Phase IIIb, Open, Multicenter Study of the Immunogenicity and Safety of One Dose of GlaxoSmithKline Biologicals Inactivated Hepatitis A Vaccine (Havrix®) [720 EI U/0.5 mL dose] Administered to Healthy Children Who Were

- Seropositive for Anti-HAV prior to a Primary Vaccination Course with Havrix[®] in Study HAV-210 and to a Control Group of Healthy Children Who are Non-Immune for Hepatitis A. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: GlaxoSmithKline. 2003-2004.
8. A Phase III, Open, Multicenter Study of the Safety of Infanrix[®] When Administered as a Booster Dose at 15 to 18 Months of Age Following Primary Immunization in Studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085). Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: GlaxoSmithKline. 2003-2004.
 9. Use of Cefdinir 5-Day-Therapy and Amoxicillin-Clauvulanate ES 10-Day Therapy in Young Children with AOM. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Abbott Laboratories, 2003-2004.
 10. A Multicenter Non-Comparative, Double Tympanocentesis, Clinical Trial of Cefprozil for the Treatment of Acute Otitis Media in Children. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Bristol Meyers Squibb. 2004.
 11. An Open-Label, Non-Comparative Study of Gatifloxacin in the Treatment of Recurrent Otitis Media and Acute Otitis Media Treatment Failures in Children. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Bristol Meyers Squibb. 2004.
 12. A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media [LOFBO-OTMD-002 (PRI-LOF-INT-2) Phase 3]. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sponsor: Johnson & Johnson Pharmaceutical Research & Development. 2004-2005.
 13. A randomized, double-blind trial to assess the safety and relative efficacy of CAIV-T against activated influenza vaccine in children 6-59 months of age. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Medimmune, 2004-2005.
 14. Multinational, randomized, double-blind, double-dummy, comparative study to evaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or 10 days depending on age and previous treatment history versus cefuroxime axetil 15 mg/kg, given twice daily for 10 days, in children with acute otitis media. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . Aventis Pharmaceuticals, Inc., 2005-2006.
 15. A phase III, investigator-blind, randomized, parallel-group, multicenter study to evaluate the safety and efficacy of APC-231 mp sprinkle po qd for 7 days compared to penicillin vk 10 mg/kg po qid for 10 days in the treatment of tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in pediatric patients. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . Avancis Pharmaceutical Corp, 2005.

16. Multinational, randomized, double-blind, double-dummy, comparative study to evaluate the efficacy and safety of telithromycin (25 mg/kg qd) for 5 or 10 days, versus azithromycin for 5 days, in children with acute otitis media (AOM). Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . Sanofi-Aventis, 2005-2006.
17. A phase II, single-blinded, randomized, controlled, multi-center primary and booster vaccination study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' *Haemophilus influenzae* type b and *Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCy-TT) compared to *ActHIB*, each co-administered with *Pediarix* and *Prevnar*, in healthy infants at 2, 4, and 6 months of age and in healthy toddlers at 12 to 15 months of age (booster dose), when co-administered with *Prevnar*. An exploratory control group will receive licensed *Menomune* at 3 to 5 years of age. Hib-MenCY-TT-005 101858/005 (Primary vaccination) Hib-Men-CY-TT-006. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . GlaxoSmithKline, 2005-2006.
18. Persistence of bactericidal antibodies in children aged 7 to 15 years who received a single dose of Menactra™ or Menomune®-A/C/Y/W-135 five years earlier. A Phase 4, open-label, controlled, multicenter study. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D, Sanofi Pasteur, 2006-2007.
19. Symptomatic relapse of group A streptococcal tonsillopharyngitis in children. Principal Investigator: Michael E. Pichichero, MD; Co-investigator: Janet R. Casey, MD. Abbott Labs, 2006-2007.
20. Immunogenicity and safety of meningococcal (Serogroups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra®) in children aged 4 to 6 years in the US when administered concomitantly with a fifth dose diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed. A Phase II, randomized, modified double-blind, 3-arm, parallel-group, comparative, multicenter study in the US. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . Sanofi Pasteur, 2006-2007.
21. A phase IIIb, randomized, open, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 vaccine co-administered intramuscularly with GlaxoSmithKline Biologicals *Boostrix*® vaccine and/or Sanofi-Aventis' *Menactra*™ vaccine according to different dose schedule combinations as compared to the administration of HPV vaccine, *Boostrix* or *Menactra* alone in healthy female subjects aged 11-18 years. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. GlaxoSmithKline, 2006-2007.
22. An immunogenicity and safety evaluation of two doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) given to healthy subjects at 9 and 12 months of age. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sanofi Pasteur, 2006-2007.
23. A phase II, open, controlled multicenter study to evaluate the long-term antibody persistence at 1, 3, and 5 years after the administration of a booster dose of Hib-MenCY-TT-006. 107824 (Hib-MenCY-TT-013 EXT:006 Y1), 107826 (Hib-MenCY-TT-014 EXT:006 Y3), 107829 (Hib-MenCY-TT-015 EXT:006

- Y5). Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. GlaxoSmithKline, 2006-2007.
24. A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix[®] [720El.U/0.5 mL dose] administered on a 0, 6-month schedule concomitantly with Merck and Company, Inc. measles-mumps-rubella vaccine (M-M-R[®]_{II}) and Merck and Company, Inc. varicella vaccine (*VARIVAX*[®]) to healthy children 15 months of age. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. GlaxoSmithKline, 2006-2007.
25. Tdap 0.3-006 (105753) A phase IV, randomized, partially blinded multicenter study to evaluate the safety and immunogenicity of a booster vaccination with GlaxoSmithKline's tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed [Tdap Boostrix[®]] co-administered intramuscularly with Aventis-Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra[™]) as compared to the administration of either vaccine alone in healthy adolescents 11-18 years of age. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. . GlaxoSmithKline, 2006-2007.
26. A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6 and 12-15 months of age. 103813 (Hib-MenCY-TT-009); 105067(Hib-MenCY-TT-010) Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. GlaxoSmithKline, 2006-2007.
27. Safety and immunogenicity of Tetanus and Diphtheria toxoids adsorbed combined with component Pertussis (TdcP) vaccine compared to Tetanus and Diphtheria toxoids adsorbed (Td) in adolescents and adults 11-64 years of age— Protocol number Td506. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Sanofi Pasteur, 2006-2007.
28. A phase 3, randomized, active-control, double-blind trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric immunizations in the United States. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Wyeth, 2006-2008.
29. The changing epidemiology of pneumococcal otitis media. Principal Investigator: Michael E. Pichichero, MD; Co-investigators: Janet R. Casey, MD, Mingtao Zeng, PhD. Thrasher Research Fund, 2006-2009.
30. The molecular epidemiology of pneumococcal otitis media. Principal Investigator: Michael E, Pichichero, MD; Co-investigators: Janet R. Casey, MD, Mingtao Zeng, PhD. Wyeth, 2006-2009.
31. NTHi Immunity in Young Children. Principal Investigator: Michael E, Pichichero, MD; Co-investigator: Janet R. Casey, MD. NIH, NIDCD, RO-1, 2006-2011.

32. Development of a pediatric pharyngitis symptom outcome assessment. Principal Investigator: Alejandro Hoberman, MD U. Pittsburg; Co-investigator: Michael E. Pichichero, MD. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Replidyne, 2006-2007.
33. Video otoscope examination of children with middle ear infections. Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. Welch Allyn, 2006-2007.
34. Phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix (GSK Biologicals) compared with Fluzone (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older). Elmwood Pediatric Group. Principal Investigator: Janet R. Casey, M.D. GSK Biologicals, 2006-2007.
35. Video otoscope examination of children with middle ear infections. Principal Investigator: Michael E. Pichichero, MD. Co-Investigator: Janet R. Casey, MD. Welch Allyn, 2006-2007
36. Phase 4 Post marketing Study Evaluating the Impact of Prevnar 13 in Reducing Acute Otitis Media and Nasopharyngeal Colonization Caused by Vaccine Serotypes of *Streptococcus pneumoniae* in Health Children. 10/1/10-12/31/15. Sponsor: Pfizer Vaccine Research
Principal Investigator: Michael E. Pichichero, MD
Role: Subcontract PI
37. The Changing Epidemiology of Pneumococcal Otitis Media. Investigator-Initiated Research Agreement: 1/1/10-12/31/15. Sponsor: Pfizer Vaccine Research
Principal Investigator: Michael E. Pichichero, MD
Role: Subcontract PI
38. NTHi Immunity in Young Children. Principal Investigator: Michael E, Pichichero, MD; Co-investigator: Janet R. Casey, MD. NIH, NIDCD, RO-1DC00867. 2011-2017.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

American Academy of Pediatrics, Fellow, 1990-present
 American Society of Hematology, Member, 1993-2008
 Monroe County Medical Society, 1996-present
 Rochester Academy of Medicine, 1996-present
 Rochester Pediatric Society, 1996-present

COMMITTEE MEMBERSHIPS

Rochester Community Pediatric Guideline Committee, 1999-2007

Rochester Individual Practice Association, Pediatric Advisory Committee, 2001-2005,
Chair 2004-2005.

Town Gown Committee, Department of Pediatrics, 2003-2007

Board of Directors YMCA of Greater Rochester NY, Southeast Branch, 2010-present

BIBLIOGRAPHY

Articles

1. Ware R, Kinney TR, **Casey J**, et al. Laparoscopic cholecystectomy in young patients with sickle hemoglobinopathies. *J. Pediatrics* 120:58-61, 1992.
2. **Casey JR**, Kinney TR, Ware RE. Acute splenic sequestration in the absence of palpable splenomegaly. *Am J Peds Heme-Onc* 16:181-182, 1994.
3. **Casey JR**, Petranks JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor (uPAR) gene. *Blood* 18 (4): 1151-1156, 1994.
4. Kurtzberg J, Graham M, **Casey JR**, et al. The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. *Blood Cells* 20: 275-284, 1994.
5. Pichichero ME, **Casey JR**, Mayes T, et al. Penicillin failure in streptococcal tonsillopharyngitis : causes and remedies. *Pediatr Infect Dis J*, 2000; 19: 917-923.
6. **Casey JR**, Pichichero ME. Non-polio enteroviral infections. *Contemporary Pediatrics*, 2001; 18 (6): 82-88.
7. Curtin CD, **Casey JR**, Murray PC, Cleary CT, Hoeger WJ, Marsocci SM, Murphy ML, Francis AB, Pichichero ME. Efficacy of penicillin vs. amoxicillin in children with group A beta hemolytic streptococcal tonsillopharyngitis. *Clin Pediatr* 2003; 42: 219-25.
8. Pichichero ME, **Casey JR**. Defining and dealing with group A streptococcal carriers. *Contemporary Pediatrics* 2003; 20:46-56.
9. **Casey JR**, Marsocci SM, Murphy ML, Francis AB, Pichichero ME: White blood cell count can aid judicious antibiotic prescribing in acute upper respiratory infections in children. *Clin Pediatr* 2003; 42: 113-119.
10. Pichichero ME, Hoeger WJ, **Casey JR**. Azithromycin for the treatment of pertussis. *Ped Infect Dis J* 2003; 22: 847-9.

11. Curtin CD, **Casey JR**, Murray PC, et al. Efficacy of cephalexin twice vs. three times daily vs. cefadroxil once daily in children with group A beta hemolytic streptococcal tonsillopharyngitis. *Clin Pediatr* 2003; 42: 519-525.
12. **Casey JR**, Pichichero ME. Meta-analysis of cephalosporins versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. *Pediatrics* 2004; 113 (4): 866-882.
13. **Casey JR**, Pichichero ME. Meta-analysis of cephalosporins versus penicillin treatment of group A streptococcal tonsillopharyngitis in adults. *Clinical Infectious Disease* 2004; 38: 1526-1534
14. **Casey JR**, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. *Ped Infect Dis J* 2004; 23(9): 824-828.
15. Perrin EM, Murphy ML, **Casey JR**, Pichichero ME, Runyan DK, Swedo SE. Does group A b-hemolytic streptococcal infection increase risk for behavioral and neuropsychiatric symptoms in children? *Arch Pediatr Adolesc Med* 2004; 158: 848-56.
16. Pichichero ME, **Casey JR**. A review of recent guidelines for managing acute otitis media and the role of newer antimicrobials. *J Fam Practice* Vol 54, (4) April 2005.
17. Pichichero ME, **Casey JR**, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T. A comparative trial of the safety and immunogenicity of quadrivalent A,C,Y,W-135 Meningococcal Diphtheria Conjugate vaccine versus quadrivalent polysaccharide vaccine in 2-10 year old children. *Pediatr Infect Dis J* 2005; 24(1): 57-62.
18. **Casey JR**, Pichichero ME. Higher Dosages of Azithromycin are More Effective in Group A Streptococcal Tonsillopharyngitis Treatment. *Clin Infect Dis* 2005; 40:1748-55.
19. **Casey JR**, Pichichero ME. Update of the safety and efficacy of acellular versus whole cell pertussis vaccines. *Drugs* 2005; 65 (10): 1367-89.
20. Pichichero ME, **Casey JR**. Acellular Pertussis Vaccines for Adolescents. *Pediatr Infect Dis J* 2005;24: S117-26.
21. **Casey JR**, Pichichero ME. Meta-analysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis. *Ped Infect Dis J* 2005;24 (10): 909-17.
22. **Casey JR**. Treatment of AOM Post-PCV-7: Judicious Antibiotic Therapy. *Contemporary Pediatrics* 2005;22(12):S16-S23.
23. **Casey JR**. Treating Acute Otitis Media Post-PCV-7: Judicious Antibiotic Therapy. *Postgraduate Medicine*. December 2005:24-31.
24. **Casey JR**, Pichichero ME. European Compared to United States Results in Cephalosporin Versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis. *European Journal of Clinical Microbiology and Infectious Disease* 2006 June;25(6):354-64.

25. Pichichero ME, **Casey JR**, Francis AB, Marsocci SM, Murphy M, Hoeger W, Cleary C. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: Safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. *Clinical Ped* 2006;45(7):613-620.
26. Pichichero ME, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, **Casey JR**, Gilmet G. Immune Memory in Children Previously Vaccinated with an Experimental Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine. *Pediatr Inf Dis J* 2006;25:995-1000.
27. **Casey JR**, Pichichero ME. Symptomatic Relapse of Group A Beta-Hemolytic Streptococcal Tonsillopharyngitis in Children, *Clinical Pediatrics* 2007;46(4):307-310.
28. Pichichero, ME, **Casey JR**. Safe use of selected cephalosporins in penicillin-allergic patients: A meta-analysis. *Oto-Head Neck Surg* 2007;136:340-347.
29. Pichichero ME, **Casey JR**. Evolving Microbiology and Molecular Epidemiology of Acute Otitis Media in the Pneumococcal Conjugate Vaccine Era. *PIDJ* 2007;26(10):S12-S16.
30. Pichichero, ME, **Casey JR**. Systematic Review Factors Contributing to Penicillin Treatment Failure in *Streptococcus Pyogenes* Pharyngitis. *Otolaryngology Head & Neck Surgery* 2007;137(6):851-857.
31. Pichichero ME, **Casey JR**. Bacterial eradication rates with shortened courses of 2nd- and 3rd-generation cephalosporins versus 10 days of penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. *Diagnostic Microbiology and Infectious Disease* 2007;59:127-130.
32. Pichichero, ME, **Casey JR**. Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7 Valent Conjugate Vaccine as a Causative Otopathogen in Children. *JAMA* 2007;298(15):1772-1778.
33. Pichichero ME, **Casey JR**. Diagnostic Inaccuracy and Subject Exclusions Render Placebo and Observational Studies of Acute Otitis Media Inconclusive. *Pediatr Infect Dis J*. 2008;27:958-62.
34. Pichichero ME, **Casey JR**. Comparison of study designs in acute otitis media trials. *Int J Pediatr Otorhinolaryngol*. 2008;72:737-50.
35. Pichichero ME, **Casey JR**, Block S, et al. Clinical Trial of Amoxicillin Sprinkle for 7 Days Compared to Penicillin VK for 10 Days in the Treatment of Tonsillopharyngitis due to *Streptococcus Pyogenes* in Children with a Pharmacodynamic Analysis of Results. *Antimicrobial Agents and Chemotherapy*. 2008;52:2512-2420.
36. **Casey JR**, Kahn R, Gmoser D, Atlas E, Urbani K, Luber S, Pellman H, Pichichero ME, "Frequency of Symptomatic Relapses of Group A {beta}-Hemolytic Streptococcal Tonsillopharyngitis in Children from 4 Pediatric

- Practices Following Penicillin, Amoxicillin, and Cephalosporin Antibiotic Treatment. Clin Pediatr (Phila). 2008;47:549-554.
37. Pichichero ME, **Casey JR**, Hoberman A, Schwartz R. Pathogens causing recurrent and difficult-to-treat acute otitis media” 2003-2006. Clin Pediatr 2008;47:901-906.
 38. **Casey JR**, Pichichero ME. A Comparison of 2 White Blood Cell Count Devices to Aid Judicious Antibiotic Prescribing. Clin Pediatr 2009 Apr;48(3):291-4.
 39. Sabirov A, **Casey JR**, Murphy TF and Pichichero ME. Breast-feeding is Associated with a Reduced Frequency of Acute Otitis Media and High Serum Antibody Levels Against NTHi and Outer Membrane Protein Vaccine Antigen Candidate P6. Pediatr Res 2009;66(5):565-70.
 40. Shaikh N, Martin JM, **Casey JR**, Pichichero ME et al. Development of a patient-reported outcome measure for children with streptococcal pharyngitis. Pediatrics 2009; 124 (4) e557-63.
 41. Xu Q, Pichichero ME, **Casey JR** and Zeng M. Novel Type of Streptococcus pneumoniae Causing Multidrug-Resistant Acute Otitis Media in Children. Emerg Infect Dis 2009;15(4) 547-551.
 42. Kaur R, Adlowitz DG, **Casey JR**, Zeng M, Pichichero ME. Simultaneous Assay for Four Bacterial Species Including Alloiococcus otitidis Using Multiplex-PCR in Children with Culture Negative Acute Otitis Media. Pediatr Infect Dis J 2010;29:741-745.
 43. **Casey JR**, Adlowitz DG, Pichichero ME. New Patterns in the otopathogens causing Acute Otitis Media Six to Eight Years after Introduction of Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J 2010 Apr;29(4);304-9.
 44. Pichichero ME, Kaur R, **Casey JR** et al. Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP 26 after nasopharyngeal colonization and acute otitis media in children. Vaccine 2010; 28:7184-7192.
 45. Liu K, **Casey JR**, Pichichero ME. Serum Intercellular Adhesion Molecule 1 Variations in Young Children with Acute Otitis Media. Clinical and Vaccine Immunology 2010;17(12);1909-1916.
 46. Xu Q, Kaur R, **Casey JR**, Adlowitz DG, Pichichero ME and Zeng M. Identification of *Streptococcus pneumoniae* and *Haemophilus influenzae* in culture-negative middle ear fluids from children with acute otitis media by combination of multiplex PCR and multi-locus sequencing typing. Int J Pediatr Otorhinolaryngol 2011; 75:239-244.
 47. Xu Q, Kaur R, **Casey JR**, Sabharwal V, Pelton S and Pichichero ME. Nontypeable *Streptococcus pneumoniae* as an Otopathogen. Diag Micro Infect Dis 2011; 69:200-204.

48. Chang A, Kaur R, Michel LV, **Casey JR** and Pichichero ME. *Haemophilus influenzae* Vaccine Candidate Outer Membrane Protein P6 is Not Conserved in All Strains. *Human Vaccines* 2011; 7(1) 102-105.
49. Sharma SK, **Casey JR** and Pichichero ME. Reduced Memory CD4⁺T-Cell Generation in the Circulation of Young Children May Contribute to the Otitis-Prone Condition. *J Inf Dis* 2011; 204: 645-653.
50. Kaur R, **Casey JR**, Pichichero ME. Serum Antibody Response to Three Non-typeable *Haemophilus influenzae* Outer Membrane Proteins During Acute Otitis Media and Nasopharyngeal Colonization in Otitis Prone and Non-Otitis Prone Children. *Vaccine* 2011; 29:1023-28.
51. **Casey JR**, Block S, Puthoor P, Hedrick J, Almudevar A and Pichichero ME. A Simple Scoring System to Improve Clinical Assessment of Acute Otitis Media. *Clin Pediatr* 2011; 50:632-629.
52. Kaur R, Chang A, Xu Q, **Casey JR** and Pichichero ME. Phylogenetic relatedness and diversity of non-typable *Haemophilus influenzae* in the nasopharynx and middle ear fluid of children with acute otitis media. *J Med Microbiol.* 2011;60:1841-8.
53. Kaur R, **Casey JR** and Pichichero ME. Serum antibody response to five *Streptococcus pneumoniae* proteins during acute otitis media in otitis-prone and non-otitis-prone children. *Pediatr Infect Dis J.* 2011; 30:645-650.
54. Pichichero ME, Kaur R, **Casey JR**, Xu Q, Almudevar A, Ochs M. Antibody response to *Streptococcus pneumoniae* proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children. *Hum Vaccin Immunother* 2012; 8(6) 799-805.
55. Sharma SK, **Casey JR** and Pichichero ME. Reduced serum IgG responses to pneumococcal antigens in otitis-prone children may be due to poor memory B-cell generation. *J Infect Dis* 2012;205(8):1225-9.
56. Xu Q, **Casey JR**, Chang A and Pichichero ME. When co-colonizing the nasopharynx *haemophilus influenzae* predominates over *Streptococcus pneumoniae* except serotype 19A strains to cause acute otitis media. *Pediatr Infect Dis J* 2012; 31(6):638-640.
57. Kaur R, Kim T, **Casey JR** and Pichichero ME. Antibody in Middle Ear Fluid of Children Originates Predominantly from Serum and Nasopharyngeal Secretions. *Clin Vaccine Immunol* 2012; 19(10):1593-1596.
58. **Casey JR**, Block SL, Hedrick J, Almudevar A and Pichichero ME. Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media. *Drugs* 2012; 72(15):1991-1997.
59. Xu Q, Almudevar A, **Casey JR** and Pichichero ME. Nasopharyngeal bacterial interactions in children. *Emerg Infect Dis* 2012;18(11):1738-1745.
60. Pichichero ME, **Casey JR**, Almudevar A. Reducing the Frequency of Acute Otitis Media by Individualized Care. *Pediatr Infect Dis J* 2013;32(5):473-478.

61. **Casey JR**, Kaur R, Friedel V and Pichichero ME. Acute Otitis Media Otopathogens During 2008-2010 in Rochester, NY. *Pediatr Infect Dis J* 2013; 32(8):805-809.
62. Kaur R, **Casey JR** and Pichichero ME. Relationship with Original Pathogen in Recurrence of Acute Otitis Media After Completion of Amoxicillin/Clavulanate: Bacterial Relapse or New Pathogen. *Pediatr Infect Dis J* 2013; 32(11):1159-1162.
63. Pichichero ME, **Casey JR** and Almudevar A. Non-Protective Responses to Pediatric Vaccines Occur in Children Who are Otitis Prone. *Pediatr Infect Dis J* 2013;32 (11):1163-1168.
64. Friedel V, Zilora S, Bogaard D, **Casey JR** and Pichichero ME. Five Year Prospective Study of Pediatric Otitis Media in Rochester, NY. Modeling analysis of the risk of pneumococcal colonization in the nasopharynx and infection. *Epidemiol Infect* 2013; 17:1-9.
65. **Casey JR** and Pichichero ME. Payment Analysis of Two Diagnosis and Management Approaches of Acute Otitis Media. *Clin Pediatr* 2014 Aug;53(9):854-64.
66. Kaur R, Czup K, **Casey JR**, Pichichero ME. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. *BMC Infect Dis* 2014; 14(1):640.
67. **Casey JR** and Pichichero ME. Acute Otitis Media: Update 2015. *Contemporary Pediatrics* 2015 March.
68. Kaur R, **Casey JR**, Pichichero ME. Cytokine, Chemokine, and Toll-Like Receptor Expression in Middle Ear Fluids of Children with Acute Otitis Media. *Laryngoscope* 2015; 125:E39-E44.
69. Xu Q, **Casey JR**, Pichichero ME. Higher Levels of Mucosal Antibody to Pneumococcal Vaccine Candidate Proteins Correlate with Reduced Acute Otitis Media Caused by *Streptococcus pneumoniae* in Young Children. *Mucosal Immunol* 2015;182(3):314-322.
70. Osgood R, Salamone F, Diaz A, **Casey JR**, Pichichero ME. Effect of pH and Oxygen on Biofilm Formation in Acute Otitis Media Associated NTHi Clinical Isolates. *Laryngoscope* 2015;125(9):2204-2208.
71. Morris M, Almudevar A, **Casey JR** and Pichichero ME. Familial and Microbiological Contribution to the Otitis-Prone Condition. *Int J Pediatr Otorhinolaryngol* 2015;79(12):2174-2177.
72. Ren D, Almudevar AL, Murphy TF, Lafontaine ER, Campagnari AA, Luke-Marshall N, **Casey JR** and Pichichero, ME. Serum antibody response to *Moraxella catarrhalis* proteins OMP CD, OppA, Msp22, Hag, and PilA2 after nasopharyngeal colonization and acute otitis media in children. *Vaccine* 2015; 33(43):5809-5814.

73. Xu Q, **Casey JR**, Newman E and Pichichero ME. Otitis-Prone Children have Immunologic Deficiencies in Naturally Acquired Nasopharyngeal Mucosal Response after Streptococcus pneumoniae colonization. *Pediatr Infect Dis J* 2016; 35(1):54-60.
74. Pichichero ME, **Casey JR**, Almudevar A, Basha S, Surendran N, Kaur R, Morris M, Livingstone A and Mosmann T. Functional Immune Cell Differences Associated with Responses in Infants. *J Infect Dis* 2016; 213(12):2014-2019.
75. Kaur R, **Casey JR** and Pichichero ME. Emerging Streptococcus pneumonia strains colonizing the Nasopharynx in Children after 13-valent (PCV13) Pneumococcal Conjugate Vaccination in Comparison to the 7-Valen (PCV7) Era, 2006-2015. *Pediatr Infect Dis J* 2016; 35(8):901-906.

Chapters, Reviews

1. Pichichero ME, Casey JR. Otitis Media. In *Expert Opinion Pharmacother*. 2002; 3(8): 1073-1090.
2. Pichichero ME, Casey JR. Sinusitis, Otitis Media and Mastoiditis. In Baddour L and Gorbach S (ed). Therapy of Infectious Diseases, 2003; 43-85.
3. Pichichero ME, Casey JR. Tonsillopharyngitis, Bacterial Tracheitis, Epiglottitis and Laryngotracheitis. In: Baddour L and Grobach S (ed). Therapy of Infectious Diseases, 2003; 87-115.
4. Pichichero ME, Casey JR. Acute Otitis Media Disease Management. *Minerva Pediatrica PDR* 2003, 55 (5): 415-438.
5. Bluestone CD, Casey JR. Otitis Media. In: Feigin & Cherry's Textbook of Pediatric Infectious Diseases, 8th edition, In print.

International and National Conference Presentations

1. *Casey JR, Petrank JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor (uPAR) gene. Annual Meeting of the American Society of Hematology, 1993.
2. *Casey JR, Stockwell J, Trant C, McCowage G, Hansell D, Greenley W, Kinney TR. Successful use of extracorporeal membrane oxygenation in ACS complicating sickle cell anemia. 19th Annual Meeting of the National Sickle Cell Program, 1993.
3. Casey JR, et al. White blood cell (WBC) count can aid judicious antibiotic prescribing in acute respiratory infections in children. Pediatric Academic Societies Annual Meeting, Baltimore, Maryland, *Pediatr Res*, 2001; 169A.

4. Casey JR, et al. White blood cell (WBC) count can aid judicious antibiotic prescribing in acute respiratory infections in children. Pediatric Academic Societies Annual Meeting, Baltimore, Maryland, *Pediatr Res*, 2001; 169A.
5. *Murphy ML, Casey JR, Pichichero ME. PANDAS in primary care practice: Presenting complaints, clinical and lab findings of 25 patients with new onset PANDAS, Pediatric Academic Societies Annual Meeting, Baltimore, Maryland, *Pediatr Res* 2002; 1614.
6. *Pichichero ME, Casey JR, Papa T. A comparative trial of the safety and immunogenicity of tetravalent (A, C, Y, W-135) meningococcal diphtheria conjugate vaccine (TetraMenD) versus tetravalent polysaccharide vaccine (Menomune) in children. 43rd ICAAC 2003, Chicago, IL.
7. *Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in adults. 43rd ICAAC 2003, Chicago, IL.
8. *Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. 43rd ICAAC 2003, Chicago, IL.
9. *Pichichero ME, Casey JR, Hoeger WJ. Efficacy of azithromycin for eradication of pertussis with an assessment of disease morbidity and work productivity. 43rd ICAAC 2003, Chicago, IL.
10. *Pichichero ME, Casey JR. Comparison of a novel quadrivalent (A, C, Y, W-135) meningococcal diphtheria conjugate vaccine (MCV-4) with quadrivalent polysaccharide vaccine (Menomune®) in 2-10-year-old children. 2003, Chicago, IL.
11. *Pichichero ME, Casey JR, Papa T, Ryall R, Bybel MJ. A tetravalent (A, C, Y, and W-135) meningococcal diphtheria toxoid conjugate vaccine, MCV-4, establishes immune memory in 2- to 3- year-old children after a single dose. 2004, 44th Annual ICAAC Meeting, Washington, DC.
12. *Casey JR, Pichichero ME. Meta-analysis of shortened antibiotic therapy for group A streptococcal tonsillopharyngitis. 2004, 44th Annual ICAAC Meeting, Washington, DC.
13. *Casey JR, Pichichero ME. Higher dosages of azithromycin are required for optimal treatment of group A streptococcal tonsillopharyngitis. 2004, 44th Annual ICAAC Meeting, Washington, DC.
14. *Casey JR, Pichichero ME. European Compared to United States Results in Cephalosporin Versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis 2005, 45th Annual ICAAC Meeting, Washington DC.
15. *Casey JR, Pichichero ME. Symptomatic Relapse of Group A Beta-Hemolytic Streptococcal Tonsillopharyngitis in Children 2006, 46th Annual ICAAC Meeting, San Francisco CA.
16. *Casey JR, Pichichero ME, Hoberman A, Schwartz R. Continuing Shifts in the Pathogens Causing Acute Otitis Media in 2004-2006 2007, 9th International Symposium on Recent Advances in Otitis Media, St. Petersburg Beach FL.

17. *Casey JR, Pichichero ME. Otopathogen Distribution in the US Following Introduction of the Pneumococcal Conjugate Vaccine-7 Valent (PCV7) 2007, 47th Annual ICAAC Meeting, Chicago IL.
18. *Pichichero ME, Casey JR. Discovery of a New Multiresistant 19A Pneumococcal Strain Not Included in the 7 Valent Conjugate Vaccine (PCV7) as an Otopathogen 2007, 47th Annual ICAAC Meeting, Chicago IL.
19. *Casey JR, Adlowitz DG, Pichichero ME. . Comparison of Pathogens Causing Acute Otitis Media in Children with 1st or 2nd AOM Episode versus AOM Episodes from Otitis Prone Children 2008, 48th Annual ICAAC/IDSA Meeting, Washington DC.
20. *Casey JR, Block SI, Puthoor P, Hedrick J, Almudevar A, Pichichero ME. New Acute Otitis Media Symptom Score System Produces Superior Differentiation of Clinical Cure versus Failure Outcomes 2008, 38th Annual ICAAC/IDSA Meeting, Washington DC.
21. *Casey JR, Adlowitz DG, Pichichero ME. Nasopharyngeal Colonization and Acute Otitis Media Caused By Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis Among Children Six to Eight Years After Pneumococcal Conjugate Vaccine Introduction. 49th ICAAC Meeting September, 2009.
22. Pichichero ME and *Casey JR. Redefining the Otitis Prone Phenotype in Children. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
23. *Casey JR, Block S, Puthoor P, Hedrick J, Almudevar A and Pichichero ME. A Simple Scoring System to Improve Clinical Assessment of Acute Otitis Media. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
24. Sharma S, Kaur K, *Casey JR and Pichichero ME. Lack of Generation of T helper Cell Memory to Pneumococcal and Haemophilus influenzae Proteins in Early Childhood Explains Immunologic Susceptibility to the Otitis-Prone Condition. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
25. *Casey JR, Block S, Hedrick J, Almudevar A and Pichichero ME. Comparison of Amoxicillin/Clavulanate High Dose to Cefdinir in Treatment of Acute Otitis Media. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
26. Kaur R, *Casey JR and Pichichero ME. Differential Expression of Non-typeable Haemophilus influenzae Key Virulence Genes from Nasopharyngeal and Middle Ear Fluid samples of Children with Acute Otitis Media. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
27. Pichichero ME, Kaur R, *Casey JR, Xu Q, Almudevar A and Ochs M. Antibody Response to Streptococcus pneumoniae Vaccine Targets PhtD, LytB, PcpA, PhtE

- and PlyD1 After Nasopharyngeal Colonization and Acute Otitis Media in Children. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
28. Kaur R, *Casey JR and Pichichero ME. Serum Antibody Response to Five Vaccine Candidate Proteins of *S. pneumoniae* During Acute Otitis Media in Otitis Prone and Non-Otitis Prone Children. 10th International Otitis Media Symposium. New Orleans, June 5-9, 2011.
 29. Pichichero ME, *Casey JR, Center K, Chen L, Mathur P, Durham K, Gurtman A and Scott DA. Efficacy of PCV13 in Prevention of AOM and NP Colonization in Children: First Year of Data from the U.S. 8th International Symposium on *Pneumococci* and *Pneumococcal* Diseases. Iguacu Falls, Brazil. March 11-15, 2012.
 30. Pichichero ME, *Casey JR and Almudevar A. Non-Protective Responses to Pediatric Vaccines Occur in Children Who are Otitis Prone. Federation of Clinical Immunology Societies (FOCiS). Boston Massachusetts, June 27-30, 2013.
 31. *Xu Q, Casey JR and Pichichero ME. Higher Natural Induced Mucosal Antibody Levels to Pneumococcal Protein recombinant Vaccine (PPrV) Correlate with Protection from Acute Otitis Media Caused by *Streptococcus pneumoniae* (*Spn*) in Young Children. 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC) September 5-9, 2014, Washington, DC.
 32. Kaur R, *Casey JR, Dhaliwal S, Center K, Scott D, and Pichichero ME. Multiple Non-Vaccine Serotypes of *Streptococcus pneumoniae* Emerge During the 7-Valent (PCV7) and 13-Valent (PCV13) Pneumococcal Conjugate Vaccination – Rochester, NY – 2006- 2014. 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC) September 5-9, 2014, Washington, DC.
 33. *Kaur R, Czup K, Casey JR and Pichichero ME. Differences in nasopharyngeal cultures prior to and at onset of Acute Otitis Media and correlation with middle ear fluid cultures. 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC) September 5-9, 2014, Washington, DC.
 34. *Casey JR, Kaur, R and Pichichero ME. Multiple Non-Vaccine Serotypes of *Streptococcus pneumoniae* Emerge During the 7-Valent (PCV7) and 13-Valent (PCV13) Pneumococcal Conjugate Vaccination- Rochester, NY 2006-2014. International Society for Otitis Media (ISOM) June 7-11, 2015, Washington, DC.
 35. *Casey JR, Kaur R and Pichichero ME. Otopathogens Causing Acute Otitis Media in the 13-Valent Pneumococcal Conjugate Vaccine Era. International Society for Otitis Media (ISOM) June 7-11, 2015, Washington, DC.

36. *Casey JR, Kaur R, Zagursky R and Pichichero ME. Increased Incidence of Respiratory Illnesses in Otitis Prone Children. International Society for Otitis Media (ISOM) June 7-11, 2015, Washington, DC.
37. *Morris M, Casey JR, Almudevar A and Pichichero ME. Does the otitis prone condition show familial predisposition? International Society for Otitis Media (ISOM) June 7-11, 2015, Washington, DC.
38. *Kaur R, Kennedy R, Casey JR and Pichichero ME. Differential Characterization of Gene Expression Patterns in PBMC of Children who have Recurrent Middle Ear Infections Compared to Non-otitis Prone. ASM Microbe June 16-20, Boston.
39. *Kaur R, Casey JR and Pichichero ME. Differences in Innate Immune Response in the Middle Ear of Otitis Prone and Non-otitis Prone Children. ASM Microbe June 16-20, Boston.
40. *Xu Q, Casey JR, Almudevar A and Pichichero ME. Naturally Acquired Mucosal Antibody Levels to Pneumococcal Protein Vaccine Candidates Prevent Acute Otitis Media Caused by Streptococcus pneumoniae In Young Children. ASM Microbe June 16-20, Boston.

* Presented at National Meeting